Manufacturing

Manufacturing

R-Pharm’s production designed with account to all latest GMP requirements, which is unprecedented for Russia, especially for the production of aseptic injection drug formulations.

Новости

R-Pharm and AbbVie Announce Launch of Project on Localization of Production of Viekira Pak to Treat Chronic Hepatitis C in Russia

news

R-Pharm and AbbVie announce the launch of a project on localization of production of Viekira Pak to treat chronic hepatitis C virus (HCV) in Russia. The project aids to achieve the goals and objectives of the state strategy “Pharma 2020”. The number of patients with hepatitis C in Russia is up to 4,7 mln people, which makes this disease one of the most important challenges of the public healthcare.

Aug. 16, 2016

R-Pharm Participates in Forum on Strategic Initiatives

R-Pharm Participates in Forum on Strategic Initiatives

On July 21st -22nd at VDNKh there took place a Forum on Strategic Initiatives devoted to shaping a conception of a long term social economic development of Russia up to 2035. R-Pharm group introduced its exhibition stand of achievements while the company employees took part in the business program.

July 27, 2016

R-Pharm Group Completes Development of Drug for Treatment of Epilepsy

news

There has been finished the analysis of clinical findings of antiepileptic drug, i.e. valproic acid. The research findings proved the equivalence of the generic drug designed for the treatment of various forms of epilepcy and the foreign original. By 2017 R-Pharm group plans to register the drug in the Russian Federation and to start commercial production at a modern manufacturing facility in Russia that meets the international quality standards.

July 12, 2016

R-Pharm Brings to Market Antipsychotic Drug

news

R-Pharm group has received marketing authorization ЛП-003560 dd. 12.04.2016 issued by Ministry of Health of the Russian Federation for Periciazine drug. The drug is an antipsychotic agent and it belongs to phenothiazine class of the piperidine group designed for the treatment of acute and chronic psychotic disorders.

July 5, 2016

Big Step is Taken Towards Cure of Patients Suffering from Chronic Hepatitis C

Big Step is Taken Towards Cure of Patients Suffering from Chronic Hepatitis C

Brystol Myers Squibb company and R-Pharm group concluded an agreement on allocation of production of Daclatasvir, an innovative highly efficient drug for the treatment of the chronic hepatitis C, at R-Pharm manufacturing facilities.

June 30, 2016
News Archive →